Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Is the Fabry Disease Market Growth Potential Across Different Regions?
The fabry disease market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increased awareness and diagnosis of rare diseases, growth in specialized healthcare infrastructure, government incentives and orphan drug designations, increasing funding for rare disease research, and initial launches of therapies.
The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the expansion of newborn screening programs, regulatory support for orphan and rare disease drugs, expansion of healthcare access, growth of telemedicine and remote care, and growing demand for personalized medicine. Major trends in the forecast period include adoption of enzyme replacement therapy, advancement in genetic testing, integration of AI and digital tools for early detection, AI-powered diagnostic algorithms, and gene therapy advancement.
Claim your free report sample now:
What Are the Critical Growth Contributors in the Fabry Disease Market?
A growing focus on personalized medicine is expected to propel the growth of the fabry disease market going forward. Personalized medicine is an approach to treatment that uses information about a person's genes, environment, and lifestyle to tailor medical care and therapies specifically to them for better outcomes. Rising focus on personalized medicine is driven by its ability to improve treatment effectiveness and reduce side effects by tailoring therapies to individual patient needs. Personalized medicine helps tailor treatment plans based on a patient’s specific genetic mutation and disease severity, improving outcomes and minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, In 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, a growing focus on personalized medicine drives the growth of the fabry disease market.
Which Segments Are Attracting Maximum Investment in the Fabry Disease Market?
The fabry disease market covered in this report is segmented –
1) By Type: Type 1, Type 2, Other Types
2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments
3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease
2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease
3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease
Which Emerging Trends Are Driving the Fabry Disease Market?
Major companies operating in the fabry disease market are focusing on developing innovative therapies such as PEGylated enzyme replacement therapy (ERT) to enhance treatment efficacy, improve patient compliance, and reduce immunogenic responses associated with conventional ERTs. PEGylated enzyme replacement therapy (ERT) is a modified form of traditional ERT in which polyethylene glycol (PEG) chains are attached to the enzyme to increase its stability, prolong circulation time in the body, and reduce immune system reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Chiesi Group, an Italy-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA), a US-based government agency approval for PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval is supported by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy’s efficacy in reducing renal Gb3 deposits and maintaining kidney function while exhibiting a favorable safety profile.
Which Are the Major Market Players in the Fabry Disease Industry?
Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH
Get the full fabry disease market report here:
Which Regions Are Forecasted to Experience the Fastest Growth in the Fabry Disease Market?
North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment